Management Change12 Aug 2026, 03:00 pm
Caplin Point Board Approves Director Re-appointments
AI Summary
Caplin Point Laboratories Ltd announced board approval for the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years from August 25, 2026, and the appointment of Mr. D. Muralidharan as Whole-Time Director for two years from August 12, 2026. Mr. Muralidharan will continue as CFO. Both appointments are subject to shareholder approval. Dr. Ganesan brings over 35 years of pharmaceutical leadership experience, while Mr. Muralidharan is a seasoned finance professional with extensive experience as CFO since 2016.
Key Highlights
- Dr. Sridhar Ganesan re-appointed as MD for two years.
- Mr. D. Muralidharan appointed as Whole-Time Director for two years.
- Mr. Muralidharan to continue as CFO alongside new role.
- Both appointments require shareholder approval.
- Changes approved at the Board meeting held on August 12, 2026.
Price Impact
More from CAPLIPOINT